Table 1 Comparison of characteristics of responders and non-responders at baseline and after 3 monthly administrations of anti-vascular endothelial growth factor (VEGF) therapy.

Eyes, n

29

21

—

25

25

—

Age, years, mean (CI)

73.3 (69.8–76.8)

73.7 (69.2–78.2)

0.89

72.2 (68.6–75.8)

70.7 (67.3–74.1)

0.54

Sex, male, n, (%)

15 (51.7)

13 (61.9)

0.48

16 (64.0)

13 (52.0)

0.4

IHD, n, (%)

3 (10.3)

0 (0.0)

0.13

2 (8.0)

3 (12.0)

0.65

Stroke, n, (%)

4 (13.8)

3 (14.3)

0.96

1 (4.0)

0 (0)

0.32

Diabetes, n, (%)

11 (37.9)

3 (14.3)

0.07

9 (36.0)

6 (24.0)

0.36

Hyperlipidaemia, n, (%)

18 (62.1)

13 (61.9)

0.99

18 (72.0)

15 (60.0)

0.38

Hypertension, n, (%)

20 (68.9)

13 (61.9)

0.61

15 (60.0)

20 (80.0)

0.13

Smoking, n, (%)

3 (10.3)

4 (19.0)

0.39

6 (24.0)

7 (28.0)

0.75

Chronic kidney disease, n (%)

0 (0)

0 (0)

—

0 (0)

0 (0)

—

VA at baseline, logMAR units, (CI)

0.89 (0.68–1.10)

0.88 (0.64–1.12)

0.94

0.89 (0.66–1.12)

0.63 (0.48–0.78)

0.07

VA at month 3, logMAR units, (CI)

0.60 (0.43–0.77)

0.71 (0.50–0.92)

0.32

0.55 (0.41–0.82)

0.65 (0.45–0.88)

0.71

VA at month 12, logMAR units, (CI)

0.50 (0.28–0.74)

0.68 (0.38–0.85)

0.51

0.52 (0.31–0.78)

0.63 (0.31–0.82)

0.52

VA change from baseline to month 3, logMAR units, (CI)

−0.26 (−0.37–−0.08)

−0.15 (−0.31–0.02)

0.31

−0.28 (−0.35 – −0.10)

−0.05 (−0.25–0.01)

0.69

VA change from baseline to month 12, logMAR units, (CI)

−0.38 (−0.45 – −0.12)

−0.14 (−0.30 − 0.02)

0.58

−0.30 (−0.35 – −0.09)

−0.03 (−0.23–0.01)

0.53

CRT at baseline, μm, (CI)

488 (407–569)

488 (402–574)

0.99

426 (367–485)

476 (427–525)

0.21

CRT at month 3, μm, (CI)

291 (252–330)

515 (399–631)

<0.01

275 (257–293)

364 (321–407)

<0.01

Lesion type, PCV, n (%)

16 (55.0)

10 (47.6)

0.12

12 (48.0)

13 (52.0)

0.82

Bevacizumab, n, (%)

21 (72.4)

20 (95.2)

0.07

25

25

—

Ranibizumab, n. (%)

1 (3.4)

—

—

—

—

—

Aflibercept, n, (%)

7 (24.1)

1 (4.8)

0.11

—

—

—